Search for dissertations about: "physiologically based biopharmaceutics modelling"

Showing result 1 - 5 of 6 swedish dissertations containing the words physiologically based biopharmaceutics modelling.

  2. 1. Hepatic Disposition of Drugs and the Utility of Mechanistic Modelling and Simulation

    Author : Erik Sjögren; Hans Lennernäs; Scott Obach; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Hepatic disposition; pharmacokinetics; mechanistic modelling; drug-drug interactions; enzyme kinetics; Vmax; Km; CLint; carrier-mediated transport; active transport; modelling; in vitro-in vivo extrapolation; physiologically based pharmacokinetic model; optimal experimental design; experimental optimization; data analysis optimization; PHARMACY; FARMACI; Biopharmacy; Biofarmaci; Biopharmaceutics; Biofarmaci;

    Abstract : The elimination of drugs from the body is in many cases performed by the liver. Much could be gained if an accurate prediction of this process could be made early in the development of new drugs. However, for the elimination to occur, the drug molecule needs first to get inside the liver cell. READ MORE

  4. 2. Drug absorption in the lungs : studies in the isolated perfused rat lung model combined with physiologically based biopharmaceutics modelling

    Author : Johanna Eriksson; Hans Lennernäs; Erik Sjögren; Helena Thörn; Ben Forbes; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pulmonary drug absorption; physiologically based biopharmaceutics modeling; pulmonary drug delivery; Biofarmaci; Biopharmaceutics;

    Abstract : Pulmonary delivery of drugs is the preferred route of administration for treatment of local lung diseases like asthma and chronic obstructive pulmonary disease. Recently, there has also been increased interest in systemic delivery of drugs via the lungs to avoid problems with low and/or variable gastrointestinal absorption, and as a needle-free alternative for drugs that cannot be ingested. READ MORE

  5. 3. First-pass Intestinal Metabolism of Drugs : Experiences from in vitro, in vivo and simulation studies

    Author : Helena Anna Thörn; Hans Lennernäs; Paul Alfred Dickinson; Brian Houston; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmacokinetics; metabolism; CYP3A4; CYP2C9; CYP2D6; UGT; glucuronidation; physiologically based pharmacokinetic model; modelling; Biopharmaceutics; Biofarmaci;

    Abstract : The bioavailability of a drug can be described as the fraction of an orally administered dose that reaches the systemic circulation and is often limited by first-pass metabolism in the gut and the liver. It is important to have knowledge about these processes since the systemic blood drug concentration is tightly connected to the effect of the drug. READ MORE

  6. 4. Biopharmaceutical investigations of doxorubicin formulations used in liver cancer treatment : Studies in healthy pigs and liver cancer patients, combined with pharmacokinetic and biopharmaceutical modelling

    Author : Ilse R Dubbelboer; Hans Lennernäs; Erik Sjögren; Hartmut Derendorf; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; drug delivery system; in vivo release; PBPK modelling; hepatocellular carcinoma; doxorubicin; transarterial chemoembolization; drug disposition; Biofarmaci; Biopharmaceutics; Farmaceutisk vetenskap; Pharmaceutical Science;

    Abstract : There are currently two types of drug formulation in clinical use in the locoregional treatment of intermediate hepatocellular carcinoma (HCC). In the emulsion LIPDOX, the cytostatic agent doxorubicin (DOX) is dissolved in the aqueous phase, which is emulsified with the oily contrast agent Lipiodol® (LIP). READ MORE

  7. 5. Clinical pharmacokinetic/pharmacodynamic modelling of 5a-reductase inhibitors for the treatment of benign prostatic hyperplasia

    Author : Per Olsson Gisleskog; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacy; FARMACI; PHARMACY; FARMACI; Biopharmaceutics; biofarmaci;

    Abstract : Dihydrotestosterone (DHT), a potent androgen necessary for the development of benign prostatic hyperplasia (BPH) is formed from testosterone by the enzyme 5α-reductase, of which there are two types. The irreversible 5α-reductase inhibitors dutasteride, which inhibits both isozymes, and finasteride, which inhibits only one, are intended for the treatment of BPH. READ MORE